Technology Assessment: Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy, Part 4. Thalidomide for Multiple Myeloma. Figure 9

Figure 9: Reporting of Paraprotein Responses Across Studies

Overall Response (=25%)^a=x%
m protein reduction:

100%=x%
≥90%^a=x%
≥75%^a=x%
≥50%^a=x%
≥25-49%^a=x%

^a. To accommodate the various ways of presenting response rates found in this literature, we have considered the Overall Response to capture responses from 25 to 100%. Sub-categories generally represent 90-99%, 75-89%, 50-74%, and 25-49%—or more inclusive if the paper was presented in that manner.

Return to Document